A Phase 2 interventional study of INCB054707 and Placebo in Prurigo Nodularis, sponsored by Incyte Corporation. Completed at 49 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Prurigo with a site in United States — 4 open to participants now, 8 under way, 4 of them phase 3. Prurigo · United States.
Among the 23 studies in Prurigo with a site in United States, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2021, is one of 5 in phase 2, and was the 10th registered.
38 studies on the registry are indexed under Prurigo; 10 are open to participants now.
Browse Prurigo studies →4 of the 23 studies in Prurigo with a site in United States are open now. Recruiting first, the newest first:
Beijing InnoCare Pharma Tech Co., Ltd. · Sites in United States, China, France and 2 more countries
Ages 18–75
Galderma R&D · Sites in United States, Germany
Ages 18+
Sanofi · Sites in United States
Ages 6 mo–17 yrs
University of Maryland, Baltimore · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Prurigo studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 12 · Phase 4 1
First in 2008; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 146 is close to the median of 135 across 31 interventional studies indexed under Prurigo.
Median enrollment 140 across the 21 interventional studies, 355 across the 2 observational. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 23 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Incyte Corporation has 6 studies filed under Prurigo — fewer than ten, so there is no comparison to draw.
3 of the studies in Prurigo with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06293053Phase 3SanofiA Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis | 2027-10-28 |
| NCT07236099Beijing InnoCare Pharma Tech Co., Ltd.Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis | 2027-03 |
| NCT06988618Galderma R&DReal-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Prurigo with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive INCB054707 Dose A for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
Drug: INCB054707
Participants will receive INCB054707 Dose B for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
Drug: INCB054707
Participants will receive INCB054707 Dose C for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
Drug: INCB054707
Participants will receive placebo for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
Drug: Placebo
Oral; Tablet
Also known as: Povorcitinib
Oral; Tablet
Percentage of Participants Achieving ≥4-point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16
Each evening, the participants assessed their worst level of itch during the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable). The Baseline Itch NRS score was determined by averaging the 7 daily Itch NRS scores before Day 1 (i.e., Day -7 to Day -1). If ≥4 of the 7 days of the daily Itch NRS scores were missing prior to Day 1, then the Baseline Itch NRS score was set to "missing." The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily Itch NRS scores before the visit day. If 4 or more daily Itch NRS scores out of the 7 days before the visit day were missing, the Itch NRS score at the visit was set to missing.
Time frame: Baseline; Week 16
Percentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) (IGA Score of 0 or 1 With a ≥2-grade Improvement From Baseline) at Week 16
The IGA for chronic prurigo considers the number of pruriginous lesions, which includes papules, nodules, plaques, umbilicated ulcers, and ulcers, and uses them as an overall severity rating on a scale of 0 to 4. 0: clear; no pruriginous lesions (0 lesions). 1: almost clear; rare palpable pruriginous lesions (approximately 1-5 lesions). 2: mild; few palpable pruriginous lesions (approximately 6-19 lesions). 3: moderate: many palpable pruriginous lesions (approximately 20-100 lesions). 4: severe; abundant palpable pruriginous lesions (over 100 lesions). The IGA-TS is defined as an IGA score of 0 or 1 with a ≥2-grade improvement from Baseline.
Time frame: Baseline; Week 16
Time to ≥4-point Improvement From Baseline in Itch NRS Score
Each evening, the participants assessed their worst level of itch during the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable). The Baseline Itch NRS score was determined by averaging the 7 daily Itch NRS scores before Day 1 (i.e., Day -7 to Day -1). If ≥4 of the 7 days of the daily Itch NRS scores were missing prior to Day 1, then the Baseline Itch NRS score was set to "missing." The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily Itch NRS scores before the visit day. If 4 or more daily Itch NRS scores out of the 7 days before the visit day were missing, the Itch NRS score at the visit was set to missing.
Time frame: up to 122 days
PC Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug.
Time frame: up to 152 days
PC Period: Number of Participants With Any ≥Grade 3 TEAE
A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and serious adverse event (SAE) reported during the study and assigned it to 1 of the following categories. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to 152 days
Extension Period: Number of Participants With Any TEAE
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug.
Time frame: up to 215 days
Extension Period: Number of Participants With Any ≥Grade 3 TEAE
A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and serious adverse event (SAE) reported during the study and assigned it to 1 of the following categories. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to 215 days
| Milestone | PC Period: Placebo | PC Period: Povorcitinib 15 mg | PC Period: Povorcitinib 45 mg | PC Period: Povorcitinib 75 mg | Extension Period: Placebo to Povorcitinib 45 mg | Extension Period: Povorcitinib 15 mg to 45 mg | Extension Period: Povorcitinib 45 mg to 45 mg | Extension Period: Povorcitinib 75 mg to 45 mg | Extension Period: Placebo to Povorcitinib 75 mg | Extension Period: Povorcitinib 15 mg to 75 mg | Extension Period: Povorcitinib 45 mg to 75 mg | Extension Period: Povorcitinib 75 mg to 75 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 37 | 36 | 36 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 32 | 29 | 31 | 33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 7 | 5 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 4 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PC Period: Placebo | PC Period: Povorcitinib 15 mg | PC Period: Povorcitinib 45 mg | PC Period: Povorcitinib 75 mg | Extension Period: Placebo to Povorcitinib 45 mg | Extension Period: Povorcitinib 15 mg to 45 mg | Extension Period: Povorcitinib 45 mg to 45 mg | Extension Period: Povorcitinib 75 mg to 45 mg | Extension Period: Placebo to Povorcitinib 75 mg | Extension Period: Povorcitinib 15 mg to 75 mg | Extension Period: Povorcitinib 45 mg to 75 mg | Extension Period: Povorcitinib 75 mg to 75 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 1 | 4 | 8 | 15 | 30 | 25 | 23 | 18 |
| Completed | 0 | 0 | 0 | 0 | 1 | 4 | 7 | 12 | 25 | 22 | 18 | 13 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 5 | 3 | 5 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Site closure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
Each evening, the participants assessed their worst level of itch during the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable). The Baseline Itch NRS score was determined by averaging the 7 daily Itch NRS scores before Day 1 (i.e., Day -7 to Day -1). If ≥4 of the 7 days of the daily Itch NRS scores were missing prior to Day 1, then the Baseline Itch NRS score was set to "missing." The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily Itch NRS scores before the visit day. If 4 or more daily Itch NRS scores out of the 7 days before the visit day were missing, the Itch NRS score at the visit was set to missing.
| percentage of participants | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving ≥4-point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16 | 8.1 (1.7 to 21.9) | 36.1 (20.8 to 53.8) | 44.4 (27.9 to 61.9) | 56.8 (39.5 to 72.9) |
The IGA for chronic prurigo considers the number of pruriginous lesions, which includes papules, nodules, plaques, umbilicated ulcers, and ulcers, and uses them as an overall severity rating on a scale of 0 to 4. 0: clear; no pruriginous lesions (0 lesions). 1: almost clear; rare palpable pruriginous lesions (approximately 1-5 lesions). 2: mild; few palpable pruriginous lesions (approximately 6-19 lesions). 3: moderate: many palpable pruriginous lesions (approximately 20-100 lesions). 4: severe; abundant palpable pruriginous lesions (over 100 lesions). The IGA-TS is defined as an IGA score of 0 or 1 with a ≥2-grade improvement from Baseline.
| percentage of participants | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) (IGA Score of 0 or 1 With a ≥2-grade Improvement From Baseline) at Week 16 | 5.4 (0.7 to 18.2) | 13.9 (4.7 to 29.5) | 30.6 (16.3 to 48.1) | 48.6 (31.9 to 65.6) |
Each evening, the participants assessed their worst level of itch during the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable). The Baseline Itch NRS score was determined by averaging the 7 daily Itch NRS scores before Day 1 (i.e., Day -7 to Day -1). If ≥4 of the 7 days of the daily Itch NRS scores were missing prior to Day 1, then the Baseline Itch NRS score was set to "missing." The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily Itch NRS scores before the visit day. If 4 or more daily Itch NRS scores out of the 7 days before the visit day were missing, the Itch NRS score at the visit was set to missing.
| days | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| Time to ≥4-point Improvement From Baseline in Itch NRS Score | NA (NA to NA) | 58.0 (16.0 to NA) | 35.0 (21.0 to NA) | 19.0 (13.0 to 47.0) |
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug.
| Participants | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| PC Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 20 | 20 | 25 | 28 |
A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and serious adverse event (SAE) reported during the study and assigned it to 1 of the following categories. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| PC Period: Number of Participants With Any ≥Grade 3 TEAE | 0 | 1 | 1 | 2 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug.
| Participants | Placebo to Povorcitinib 45 mg | Povorcitinib 15 mg to 45 mg | Povorcitinib 45 mg | Povorcitinib 75 mg to 45 mg | Placebo to Povorcitinib 75 mg | Povorcitinib 15 mg to 75 mg | Povorcitinib 45 mg to 75 mg | Povorcitinib 75 mg |
|---|---|---|---|---|---|---|---|---|
| Extension Period: Number of Participants With Any TEAE | 0 | 3 | 5 | 7 | 20 | 19 | 16 | 13 |
A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and serious adverse event (SAE) reported during the study and assigned it to 1 of the following categories. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Placebo to Povorcitinib 45 mg | Povorcitinib 15 mg to 45 mg | Povorcitinib 45 mg | Povorcitinib 75 mg to 45 mg | Placebo to Povorcitinib 75 mg | Povorcitinib 15 mg to 75 mg | Povorcitinib 45 mg to 75 mg | Povorcitinib 75 mg |
|---|---|---|---|---|---|---|---|---|
| Extension Period: Number of Participants With Any ≥Grade 3 TEAE | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 3 |
Collected over from the time of Informed Consent Form signing until at least 30 days after the last dose of study drug (up to approximately 44 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/37 (0%) | 1/37 (2.7%) | 14/37 (37.8%) |
| Povorcitinib 15 mg | 1/36 (2.8%) | 2/36 (5.6%) | 17/36 (47.2%) |
| Povorcitinib 45 mg | 0/35 (0%) | 4/35 (11.4%) | 19/35 (54.3%) |
| Povorcitinib 75 mg | 0/37 (0%) | 3/37 (8.1%) | 22/37 (59.5%) |
| Placebo to Povorcitinib 45 mg | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Povorcitinib 15 mg to 45 mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Povorcitinib 45 mg to 45 mg | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Povorcitinib 75 mg to 45 mg | 0/15 (0%) | 1/15 (6.7%) | 6/15 (40%) |
| Placebo to Povorcitinib 75 mg | 0/30 (0%) | 0/30 (0%) | 15/30 (50%) |
| Povorcitinib 15 mg to 75 mg | 0/25 (0%) | 1/25 (4%) | 15/25 (60%) |
| Povorcitinib 45 mg to 75 mg | 0/23 (0%) | 2/23 (8.7%) | 13/23 (56.5%) |
| Povorcitinib 75 mg to 75 mg | 0/18 (0%) | 3/18 (16.7%) | 13/18 (72.2%) |
| Event | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg | Placebo to Povorcitinib 45 mg | Povorcitinib 15 mg to 45 mg | Povorcitinib 45 mg to 45 mg | Povorcitinib 75 mg to 45 mg | Placebo to Povorcitinib 75 mg | Povorcitinib 15 mg to 75 mg | Povorcitinib 45 mg to 75 mg | Povorcitinib 75 mg to 75 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnxietyPsychiatric disorders | 0/37 | 0/36 | 0/35 | 0/37 | 0/1 | 0/4 | 0/8 | 1/15 | 0/30 | 0/25 | 0/23 | 0/18 |
| ErysipelasInfections and infestations | 0/37 | 0/36 | 0/35 | 0/37 | 0/1 | 0/4 | 0/8 | 0/15 | 0/30 | 0/25 | 0/23 | 1/18 |
| HidradenitisSkin and subcutaneous tissue disorders | 0/37 | 0/36 | 0/35 | 0/37 | 0/1 | 0/4 | 0/8 | 0/15 | 0/30 | 0/25 | 0/23 | 1/18 |
| MastitisInfections and infestations | 0/37 | 0/36 | 0/35 | 0/37 | 0/1 | 0/4 | 0/8 | 0/15 | 0/30 | 0/25 | 0/23 | 1/18 |
| AppendicitisInfections and infestations | 0/37 | 0/36 | 1/35 | 0/37 | 0/1 | 0/4 | 0/8 | 0/15 | 0/30 | 0/25 | 1/23 | 0/18 |
| COVID-19Infections and infestations | 0/37 | 0/36 | 0/35 | 0/37 | 0/1 | 0/4 | 0/8 | 0/15 | 0/30 | 0/25 | 1/23 | 0/18 |
| PneumoniaInfections and infestations | 0/37 | 0/36 | 0/35 | 0/37 | 0/1 | 0/4 | 0/8 | 0/15 | 0/30 | 1/25 | 0/23 | 0/18 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/37 | 0/36 | 1/35 | 0/37 | 0/1 | 0/4 | 0/8 | 0/15 | 0/30 | 0/25 | 0/23 | 0/18 |
| Nasal septum deviationRespiratory, thoracic and mediastinal disorders | 0/37 | 0/36 | 1/35 | 0/37 | 0/1 | 0/4 | 0/8 | 0/15 | 0/30 | 0/25 | 0/23 | 0/18 |
| Tooth infectionInfections and infestations | 0/37 | 0/36 | 1/35 | 0/37 | 0/1 | 0/4 | 0/8 | 0/15 | 0/30 | 0/25 | 0/23 | 0/18 |
| Event | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg | Placebo to Povorcitinib 45 mg | Povorcitinib 15 mg to 45 mg | Povorcitinib 45 mg to 45 mg | Povorcitinib 75 mg to 45 mg | Placebo to Povorcitinib 75 mg | Povorcitinib 15 mg to 75 mg | Povorcitinib 45 mg to 75 mg | Povorcitinib 75 mg to 75 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dry skinSkin and subcutaneous tissue disorders | 0/37 | 0/36 | 0/35 | 0/37 | 0/1 | 1/4 | 0/8 | 0/15 | 0/30 | 0/25 | 0/23 | 0/18 |
| Ear discomfortEar and labyrinth disorders | 0/37 | 0/36 | 0/35 | 0/37 | 0/1 | 1/4 | 0/8 | 0/15 | 0/30 | 0/25 | 0/23 | 0/18 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/37 | 0/36 | 0/35 | 0/37 | 0/1 | 1/4 | 1/8 | 0/15 | 2/30 | 0/25 | 0/23 | 0/18 |
| FatigueGeneral disorders | 1/37 | 5/36 | 3/35 | 2/37 | 0/1 | 1/4 | 0/8 | 1/15 | 2/30 | 1/25 | 0/23 | 0/18 |
| HypertensionVascular disorders | 0/37 | 0/36 | 1/35 | 0/37 | 0/1 | 1/4 | 0/8 | 0/15 | 1/30 | 1/25 | 1/23 | 1/18 |
| NasopharyngitisInfections and infestations | 3/37 | 2/36 | 2/35 | 5/37 | 0/1 | 0/4 | 2/8 | 1/15 | 3/30 | 3/25 | 0/23 | 0/18 |
| PresyncopeNervous system disorders | 0/37 | 0/36 | 0/35 | 0/37 | 0/1 | 1/4 | 0/8 | 0/15 | 0/30 | 0/25 | 0/23 | 0/18 |
| Skin candidaInfections and infestations | 0/37 | 0/36 | 0/35 | 0/37 | 0/1 | 1/4 | 0/8 | 0/15 | 0/30 | 0/25 | 0/23 | 0/18 |
| Upper respiratory tract infectionInfections and infestations | 0/37 | 1/36 | 0/35 | 0/37 | 0/1 | 1/4 | 0/8 | 0/15 | 1/30 | 1/25 | 1/23 | 0/18 |
| Weight increasedInvestigations | 0/37 | 0/36 | 1/35 | 1/37 | 0/1 | 1/4 | 1/8 | 0/15 | 3/30 | 0/25 | 1/23 | 1/18 |
| Age, Continuous(years) | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg | Total |
|---|---|---|---|---|---|
| Mean | 52.9 ± 12.32 | 56.0 ± 12.92 | 55.6 ± 15.25 | 55.9 ± 10.18 | 55.1 ± 12.70 |
| Sex: Female, Male(Participants) | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg | Total |
|---|---|---|---|---|---|
| Female | 22 | 24 | 27 | 23 | 96 |
| Male | 15 | 12 | 9 | 14 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 3 | 3 | 3 | 16 |
| Not Hispanic or Latino | 30 | 32 | 33 | 33 | 128 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg | Total |
|---|---|---|---|---|---|
| White/Caucasian | 33 | 31 | 27 | 30 | 121 |
| Black/African-American | 3 | 3 | 5 | 5 | 16 |
| Asian | 0 | 2 | 4 | 1 | 7 |
| American-Indian/Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Unknown | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Nov 2021 to primary completion in Aug 2023, 21 months.
Results were first posted in Aug 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Povorcitinib